The company currently has no drugs on the market which I would imagine no product on the market + expenses = low or declining stock price short term, however,

Their two oncology drugs Azedra and Onalta both have orphan drug status which will allow greater profits for a longer period of time once (if) they receive FDA approval.

Also, Azedra has fast track approval as well along with its orphan drug status.

I just ran a few numbers to see what kind of potential revenue they could generate from treating neuroendicrine cancer, which is what their current oncology drugs are primarily geared towards. Please feel free to refute my numbers as well if anyone feels they are off which they very well could be...

Anyways, It looks like there are roughly 9,000 new cases of neuroendicrine cancer each year. Those are new cases but for the case of this rationale lets just say there are only 9,000 people to treat in the United States each year. Now lets say Azedra and Onalta can only be applied to 1/3rd of that population. So we have 3000 people to treat each year. Now, I dont know how much conventional chemotherapy costs but I'll make an estimate that chemo drugs on average cost roughly $10,000 for any given treatment for one person in a three month period (or one fiscal quarter). And I think I might be under estimating the costs of chemo here.

Now lets say MIPI charges the same amount for their treatments, so $10,000 each fiscal quarter approximately for the medication per person. Again I think Im underestimating costs as Onalta and Azedra is a radically different technology than traditional chemotherapy, but just for the sake of argument lets stick with my assumptions.

Now we have 3000 people to be treated at $10,000 each for each fiscal quarter. That is $30,000,000 in revenue each quarter and $120,000,000 in revenue each year.

MIPIs current market cap is only $185 million, which means in one year MIPI could potentially generate revenues pretty darn close to their current market cap once their cancer drugs come to market. I also didnt even consider any revenues for Zemiva either, another drug in their pipeline for detection of cardiac ischemias. On top of that I only considered a US population, tried to underestimate all my numbers as far as who would get treatment, and the cost of Onalta and Azedra.